References
- Tefferi A, Thiele J, Orazi A, Kvasnicka H M, Barbui T, Hanson C A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097
- Gangat N, Wolanskyj A P, McClure R F, Li C Y, Schwager S, Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270–276
- Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93: 1645–1651
- Gabrail N Y, Martin T W. Coexistence of essential thrombocythemia and chronic lymphocytic leukemia. Acta Haematologica 1991; 85: 31–33
- Morla J, Pérez-Encinas M, Antela C, Pérez E, Barrio E. Histiocytic lymphoma and pulmonary fibrosis in a female patient with essential Thrombocythemia. Medicina Clinica (Barc) 1993; 100: 104–106
- Carulli G, Marini A, Baicchi U, Simi P, Papineschi F, Ambrogi F. Chronic lymphocytic leukemia (B-cell) in the course of polycythemia vera. Description of a case with an unusual chromosomic anomaly. Tumori 1987; 73: 639–643
- Carulli G, Testi C, Azzarà A. Association between non-Hodgkin's lymphoma and essential thrombocythemia. Haematologica 1997; 82: 382
- Manoharan A, Catovski D, Clein P, Traub N E, Costello C, O'Brien M, et al. Simultaneous or spontaneous occurrence of lympho- and myeloproliferative disorders: a report of four cases. Br J Haematol 1981; 48: 111–116
- Hernández-Boluda J C, Cervantes F, Alvarez A, López-Guillermo A, Montserrat E. Non-Hodgkin's lymphoma following untreated essential thrombocythemia. Leuk Lymphoma 2000; 36: 421–423
- Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39
- Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302
- Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human mieloproliferative Disorders. Lancet 2005; 365: 1054–1061
- Quentmeier H, MacLeod R AF, Zaborski M, Drexler H G. Jak2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471–476
- Kremer M, Horn T, Koch I, Dechow T, Gattenloehner S, Pfeiffer W, et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol 2008; 32: 928–935
- Catani L, Zini R, Sollazzo D, Ottaviani E, Vannucchi A M, Ferrari S, et al. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia Jan 8, 2009, [Epub ahead of print]